Weekly Recap | Biomea Fusion this week, a quiet, low-volume rangeWeekly Review·Aug 29 at 05:19 AMBMEA+6.28%
Biomea Fusion completes enrollment in COVALENT-211 Phase II icovamenib trial in insulin-deficient type 2 diabetesPUBT·Aug 24 at 11:03 AMBMEA+6.28%
Biomea Fusion doses first patient in OPAL trial of icovamenib plus semaglutide for obesityPUBT·Aug 13 at 11:03 AMBMEA+6.28%
Niche Market Moves: Major Overhauls From Energy to AI InfrastructureGlobal Report·Jul 22 at 09:17 AMWLLBW0.00%BMEA+6.28%
Unbundling the Long Tail: Narrative Arbitrage and Value Chain RealitiesGlobal Report·Jul 9 at 10:03 AMNTRB+6.04%KYCCF+0.89%
Markets Weigh Cross-Sector Fundamentals for Signals on the Next Economic PhaseGlobal Report·Jul 9 at 03:32 AMNEXA-0.36%PCRHY-0.70%
Biomea Presents Promising Phase 2 Data For Icovamenib In Diabetes; Advances Phase 1 For BMF-650nasdaq·Jun 8 at 12:10 PMBMEA+6.28%
